Cancer dormancy: Opportunities for new therapeutic approaches

[1]  L. Picker,et al.  Lymphocyte Homing and Homeostasis , 1996, Science.

[2]  L. Israel.  Tumour progression: random mutations or an integrated survival response to cellular stress conserved from unicellular organisms? , 1996, Journal of theoretical biology.

[3]  B. Lacour,et al.  Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. , 1995, Clinical chemistry.

[4]  D. Pardoll,et al.  Exposing the immunology of naked DNA vaccines. , 1995, Immunity.

[5]  G. Stingl,et al.  Dendritic cells: a major story unfolds. , 1995, Immunology today.

[6]  R. Scheuermann,et al.  Tumour dormancy and cell signalling--III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells. , 1995, Therapeutic immunology.

[7]  R. Scheuermann,et al.  Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice , 1995, The Journal of experimental medicine.

[8]  W. Miller,et al.  Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. , 1995, The Journal of urology.

[9]  Y. Ito,et al.  Clinical significance of minimal residual disease in leukemia detected by polymerase chain reaction: is molecular remission a milestone for achieving a cure? , 1994, Leukemia & lymphoma.

[10]  J. Uhr,et al.  Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. , 1994, Cancer research.

[11]  J. Cyster,et al.  Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire , 1994, Nature.

[12]  S. Russell,et al.  Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  G. Riethmüller,et al.  Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma , 1994, The Lancet.

[14]  G. Nossal.  Minimal residual disease as the target for immunotherapy of cancer , 1994, The Lancet.

[15]  M. Colombo,et al.  Human melanoma cells express a functional interleukin‐2 receptor , 1993, International journal of cancer.

[16]  S. Rosenberg,et al.  T-cell recognition of human melanoma antigens. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[17]  I. Penn.  The effect of immunosuppression on pre-existing cancers. , 1993, Transplantation.

[18]  R. Scheuermann,et al.  Cancer dormancy: isolation and characterization of dormant lymphoma cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[19]  G. Nicolson.  Cancer progression and growth: relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis. , 1993, Experimental cell research.

[20]  H. Metzger,et al.  Transmembrane signaling: the joy of aggregation. , 1992, Journal of immunology.

[21]  J. White,et al.  TGF‐β stimulation of endometrial and breast‐cancer cell growth , 1992 .

[22]  J. Uhr,et al.  Cancer dormancy: studies of the murine BCL1 lymphoma. , 1991, Cancer research.

[23]  R. Kerbel,et al.  Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. , 1991, Cancer research.

[24]  J. Vaage,et al.  Collagen production by macrophages in tumour encapsulation and dormancy. , 1991, British Journal of Cancer.

[25]  A. George,et al.  Anti-Idiotypic Therapy of Leukemias and Lymphomas (Part 1 of 2) , 1990 .

[26]  D. Scott,et al.  Lymphoma models for B-cell activation and tolerance: anti-immunoglobulin M treatment induces growth arrest by preventing the formation of an active kinase complex which phosphorylates retinoblastoma gene product in G1. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[27]  A. Ullrich,et al.  Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. , 1990, Cancer research.

[28]  M. Greene,et al.  Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. , 1988, Oncogene.

[29]  F. Balkwill,et al.  Enhanced metastases of a mouse carcinoma after in vitro treatment with murine interferon gamma , 1987, International journal of cancer.

[30]  J. Uhr,et al.  Tumor dormancy. I. Regression of BCL1 tumor and induction of a dormant tumor state in mice chimeric at the major histocompatibility complex. , 1986, Journal of immunology.

[31]  R. Levy,et al.  Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. , 1986, Journal of immunology.

[32]  K. Rajewsky,et al.  Isolation and characterization of anti-monosialoganglioside monoclonal antibody 19-9 class-switch variants. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[33]  I. Bernstein,et al.  Influence of antibody isotype on passive serotherapy of lymphoma. , 1985, Journal of immunology.

[34]  R. Warnke,et al.  Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. , 1985, The New England journal of medicine.

[35]  D. Scott,et al.  Lymphoma models for B-cell activation and tolerance. II. Growth inhibition by anti-mu of WEHI-231 and the selection and properties of resistant mutants. , 1985, Cellular immunology.

[36]  E. Vitetta,et al.  Suppression and elimination of BCL1 leukemia by allogeneic bone marrow transplantation. , 1983, Journal of immunology.

[37]  M. Woodruff.  The Walter Hubert Lecture, 1982. Interaction of cancer and host. , 1982, British Journal of Cancer.

[38]  H. Koprowski,et al.  IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[39]  R. Noble,et al.  A classification of transplantable tumors in Nb rats controlled by estrogen from dormancy to autonomy. , 1975, Cancer research.

[40]  S. Eccles,et al.  Immunologically-mediated restraint of latent tumour metastases , 1975, Nature.

[41]  K. Illmensee,et al.  Normal genetically mosaic mice produced from malignant teratocarcinoma cells. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. Eggers,et al.  CANCER OF THE BREAST , 1941, Annals of surgery.

[43]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[44]  M J Bissell,et al.  Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. , 1996, Physiological reviews.

[45]  N. Bouck,et al.  How tumors become angiogenic. , 1996, Advances in cancer research.

[46]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.

[47]  D. Maloney,et al.  Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. , 1994, Blood.

[48]  P. Bruggen,et al.  Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.

[49]  S. Albelda,et al.  Role of integrins and other cell adhesion molecules in tumor progression and metastasis. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[50]  P. Greenberg.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. , 1991, Advances in immunology.

[51]  R. Miller,et al.  Therapy of lymphoma directed at idiotypes. , 1990, Journal of the National Cancer Institute. Monographs.

[52]  A. George,et al.  Anti-idiotypic therapy of leukemias and lymphomas. , 1990, Chemical immunology.

[53]  J. Briggs,et al.  The incidence of late recurrence (greater than 10 years); an analysis of 536 consecutive cases of cutaneous melanoma. , 1989, British journal of plastic surgery.

[54]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[55]  K. Weinhold,et al.  The tumor dormant state. , 1981, Advances in cancer research.

[56]  J. Bingham.  Letter: Lower oesophageal sphincter. , 1974, Lancet.